[Copper (II) glycinate-L-serinate--a representative of a new class of antitumor preparations].
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003300:Copper / Q000627:therapeutic use*; D004151:Dipeptides / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D007414:Intestinal Neoplasms / Q000188:drug therapy; D007420:Intestine, Large; D007942:Leukemia, Experimental / Q000188:drug therapy; D008558:Melphalan / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009942:Organometallic Compounds
D000970:Antineoplastic Agents; D004151:Dipeptides; D009942:Organometallic Compounds; C048834:glycylserine copper(II) complex; D003300:Copper; D002945:Cisplatin; D008558:Melphalan; C043804:diamminedichlorodihydroxyplatinum IV
Glitsinato-L-serinat medi (II)--predstavitel' novogo klassa protivoopukholevykh preparatov.